BioAge Labs (BIOA) Change in Receivables (2025 - 2026)
BioAge Labs (BIOA) posted Change in Receivables of -$60000.0 for Q1 2026, down 123.62% sequentially from $254000.0 in Q4 2025, and down 116.62% YoY from $361000.0 in Q1 2025.
BioAge Labs (BIOA) Change in Receivables (2025 - 2026) Analysis & Trends
BioAge Labs has reported Change in Receivables for 2 years, with the latest figure at -$60000.0 in Q1 2026.
- Quarterly Change in Receivables fell 116.62% year-over-year to -$60000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $348000.0 (down 3.6% YoY) and the FY2025 annual result came in at $769000.0, changed N/A from the prior year.
- Change in Receivables fell to -$60000.0 in Q1 2026 per BIOA's latest filing, from $254000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $361000.0 in Q1 2025 and troughed at -$88000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioAge Labs | 434.04 Mn | 434.04 Mn | -14.23 Mn | -84,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84,000.00 |
| Jun 30, 2026 | -84,000.00 |
| Mar 31, 2026 | -60,000.00 |
| Mar 31, 2026 | -60,000.00 |
| Dec 31, 2025 | 254,000.00 |
| Dec 31, 2025 | 254,000.00 |
| Sep 30, 2025 | -88,000.00 |
| Sep 30, 2025 | -88,000.00 |
| Jun 30, 2025 | 242,000.00 |
| Jun 30, 2025 | 242,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Mar 31, 2025 | 361,000.00 |